Fate Therapeutics Inc
(NAS:FATE)
$
3.17
0.01 (0.32%)
Market Cap: 360.85 Mil
Enterprise Value: 79.38 Mil
PE Ratio: 0
PB Ratio: 0.85
GF Score: 57/100 - Q4 2023 Fate Therapeutics Inc Earnings Call TranscriptFeb 26, 2024$6.95 (-0.14%)Earnings
- Q3 2023 Fate Therapeutics Inc Earnings Call TranscriptNov 08, 2023$2.33 (+0.87%)Earnings
- Q2 2023 Fate Therapeutics Inc Earnings Call TranscriptAug 08, 2023$3.53 (-0.56%)Earnings
- Fate Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 13, 2023
- Fate Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Q1 2023 Fate Therapeutics Inc Earnings Call TranscriptMay 03, 2023$6.32 (+6.76%)Earnings
- Fate Therapeutics Inc at Barclays Global Healthcare Conference TranscriptMar 14, 2023
- Q4 2022 Fate Therapeutics Inc Earnings Call TranscriptFeb 28, 2023$6.12 (+1.83%)Earnings
- Fate Therapeutics Inc at Cowen IO Next Summit (Virtual) TranscriptNov 11, 2022
- Q3 2022 Fate Therapeutics Inc Earnings Call TranscriptNov 03, 2022$19.45 (-2.94%)Earnings
- Fate Therapeutics Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2022
- Q2 2022 Fate Therapeutics Inc Earnings Call TranscriptAug 03, 2022$32.81 (+7.12%)Earnings
- Fate Therapeutics Inc at Bank of America Healthcare Conference TranscriptMay 12, 2022
- Q1 2022 Fate Therapeutics Inc Earnings Call TranscriptMay 04, 2022$30.69 (+6.64%)Earnings
- Fate Therapeutics Inc at Barclays Global Healthcare Conference TranscriptMar 16, 2022
- Q4 2021 Fate Therapeutics Inc Earnings Call TranscriptFeb 28, 2022$34.55 (-1.09%)Earnings
- Fate Therapeutics Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) TranscriptFeb 09, 2022
- Fate Therapeutics Inc Phase 1 FT516 and FT596 Clinical Data Update Call TranscriptDec 14, 2021
- Fate Therapeutics Inc Investor Event - Corporate Call TranscriptNov 15, 2021
- Q3 2021 Fate Therapeutics Inc Earnings Call TranscriptNov 04, 2021$59.65 (-1.21%)Earnings
- Fate Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 10, 2021
- Fate Therapeutics Inc Interim Phase 1 Clinical Data for NHL Programs Call TranscriptAug 19, 2021
- Q2 2021 Fate Therapeutics Inc Earnings Call TranscriptAug 04, 2021$85.73 (+2.98%)Earnings
- Fate Therapeutics Inc at Bank of America NAPA Healthcare Conference TranscriptJun 15, 2021
- Fate Therapeutics Inc Annual Shareholders Meeting TranscriptJun 02, 2021
- Fate Therapeutics Inc at Jefferies Healthcare Conference (Virtual) TranscriptJun 01, 2021
- Fate Therapeutics Inc Interim Phase 1 Clinical Data for AML Programs Corporate Call TranscriptMay 13, 2021
- Q1 2021 Fate Therapeutics Inc Earnings Call TranscriptMay 05, 2021$77.73 (-2.51%)Earnings
- Fate Therapeutics Inc at Barclays Global Healthcare Conference (Virtual) TranscriptMar 11, 2021
- Fate Therapeutics Inc at SVB Leerink Global Healthcare Conference (Virtual) TranscriptFeb 25, 2021
- Q4 2020 Fate Therapeutics Inc Earnings Call TranscriptFeb 24, 2021$95.27 (-0.22%)Earnings
- Q3 2020 Fate Therapeutics Inc Earnings Call TranscriptNov 05, 2020$49.92 (+0.20%)Earnings
- Q2 2020 Fate Therapeutics Inc Earnings Call TranscriptAug 05, 2020$32.84 (+0.67%)Earnings
- Q1 2020 Fate Therapeutics Inc Earnings Call TranscriptMay 11, 2020$30.22 (+4.79%)Earnings
- Q4 2019 Fate Therapeutics Inc Earnings Call TranscriptMar 02, 2020$31.01 (+6.20%)Earnings
- Q3 2019 Fate Therapeutics Inc Earnings Call TranscriptNov 05, 2019$15.71 (+2.68%)Earnings
- Fate Therapeutics, Inc. Presents at Citi's 14th Annual Biotech Conference, Sep-04-2019 01:30 PM TranscriptSep 04, 2019
- Q2 2019 Fate Therapeutics Inc Earnings Call TranscriptAug 06, 2019$19.82 (+2.85%)Earnings
- Q1 2019 Fate Therapeutics Inc Earnings Call TranscriptMay 07, 2019$16.98 (-5.19%)Earnings
- Q4 2018 Fate Therapeutics Inc Earnings Call TranscriptMar 05, 2019$16.03 (-1.05%)Earnings
Fate Therapeutics Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
Feb 09, 2022 / 04:00PM GMT
Release Date Price:
$40.95
(+3.54%)
Michael Schmidt
Guggenheim Securities, LLC - Analyst
All right. Good morning and welcome. My name is Michael Schmidt. I am a senior biotech analyst with Guggenheim Securities. And it's my great pleasure to welcome Fate Therapeutics. With us today, we have Scott Wolchko, President and CEO; as well as Ed Dulac, CFO. Welcome guys, and thanks for joining us today.
Scott Wolchko
Fate Therapeutics, Inc. - President & CEO
Welcome. Thank you for having us.
Ed Dulac
Fate Therapeutics, Inc. - CFO
Welcome, Michael.
Questions & Answers
Michael Schmidt
Guggenheim Securities, LLC - Analyst
I think most of the investors are pretty familiar with Fate which has obviously been one of the pioneers in the iPSC-derived cell therapy field with several programs now in clinical development. So I thought it'd probably be most helpful to jump right into some of your clinical programs, perhaps, starting with FT516 where we have seen data most recently at ASH, an update on your
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)